Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
Brief
"On Tuesday, the National Medical Products Administration released a report stating that China approved 48 first-in-class innovative drugs. These medicines cover nearly 20 therapeutic areas, including oncology, neurological disorders, and anti-infective medicines, with 17 receiving market approval through a priority review pathway."
Highlights content goes here...
Hello!
To view this content, please sign up or log in – it’s free and easy! Stay ahead with curated regulatory insights designed for professionals like you.
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
